Drug Information

Drug (ID: DG00426) and It's Reported Resistant Information

• Name: Enrofloxacin
• Synonyms: Enrofloxacin; 93106-60-6; Baytril; Enrofloxacine; CFPQ; Enrofloxacino; Enrofloxacinum; BAY VP 2674; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Enroxil; UNII-3DX3XEK1BN; Baytril (TN); N-Ethylciprofloxacin; ERFX; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; C19H22FN3O3; MFCD00792463; 3DX3XEK1BN; 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-; MLS000069441; CHEBI:35720; NSC-758616; BAY Vp 2674;PD160788; endrofloxicin; NCGC00018143-04; CPD000059011; PD160788; SMR000059011; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid; DSSTox_CID_25619; DSSTox_RID_81007; DSSTox_GSID_45619; 3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-; Enrofloxacine [French]; Enrofloxacinum [Latin]; Enrofloxacino [Spanish]; Bay-Vp-2674; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic Acid; CAS-93106-60-6; Enrofloxacin [USAN:BAN:INN]; HSDB 6952; BRN 5307824; CCRIS 8214; Enrofloxacin [USAN:USP:INN:BAN]; Enrofloxacin-[d5]; Opera_ID_1106; Enrofloxacin (USP/INN); Enrofloxacin (USAN/INN); 1,4-Dihydro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-3-quinolinecarboxylic acid; BAY-Vp2674; MLS001076496; MLS001424169; CHEMBL15511; SCHEMBL149150; SPECTRUM1503721; Enrofloxacin for veterinary use; DTXSID1045619; HMS2052O09; HMS2090E12; HMS2093I21; HMS2234M11; HMS3373P14; HMS3394O09; HMS3715B18; Pharmakon1600-01503721; ZINC597112; ALBB-030792; BCP15457; HY-B0502; Enrofloxacin, >=98.0% (HPLC); Tox21_110831; BBL009982; DL-384; HTS028366; NSC758616; s3059; STK711109; AKOS005530685; BAY-Vp2674;PD160788; Tox21_110831_1; AC-7614; CCG-101102; DB11404; KS-5010; MCULE-6446074322; NC00352; NSC 758616; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-quinoline-3-carboxylic acid; 1-cyclopropyl-7-(4-ethylpiperazinyl)-6-fluoro-4-oxohydroquinoline-3-carboxylic acid; NCGC00018143-01; NCGC00018143-02; NCGC00018143-03; NCGC00018143-05; NCGC00021632-03; H734; SBI-0206725.P001; AB0013220; DB-057368; B1742; E0786; FT-0625663; FT-0667862; D02473; AB00384269-16; AB00384269_17; AB00384269_18; Enrofloxacin, VETRANAL(TM), analytical standard; 106E606; A844445; Q414413; SR-01000000045; SR-01000000045-3; BRD-K76534306-001-11-0; Enrofloxacin, European Pharmacopoeia (EP) Reference Standard; Enrofloxacin, United States Pharmacopeia (USP) Reference Standard; 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-3-quinolinecarboxylic acid; Enrofloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard; Enrofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-3-quinoline-carboxylic acid; 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-3-quinolinecarboxylic acid; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3- quinolonecarboxylic acid; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, 9CI; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoranyl-4-oxidanylidene-quinoline-3-carboxylic acid
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Melioidosis [ICD-11: 1C42]; [1], [2]
• Formula: C19H22FN3O3
• IsoSMILES: CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F
• InChI: 1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)
• InChIKey: SPFYMRJSYKOXGV-UHFFFAOYSA-N
• PubChem CID: 71188
• VARIDT ID: DR01565
• DrugBank ID: DB11404

Type(s) of Resistant Mechanism of This Drug

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Melioidosis [ICD-11: 1C42]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: Outer membrane porin (OMP38) [1], [2]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Melioidosis [ICD-11: 1C42.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Escherichia coli; 668369
• In Vitro Model: Escherichia coli BL21(DE3); 469008
• In Vitro Model: Burkholderia pseudomallei isolates; 28450
• Experiment for Molecule Alteration: Whole genome sequence assay
• Experiment for Drug Resistance: Broth microdilution method assay
• Mechanism Description: Bps is highly resistant to many antimicrobial agents and this resistance may result from the low drug permeability of outer membrane proteins, known as porins.An Escherichia coli strain defective in most porins, but expressing BpsOmp38, exhibited considerably lower antimicrobial susceptibility than the control strain. In addition, mutation of Tyr119, the most prominent pore-lining residue in BpsOmp38, markedly altered membrane permeability, substitution with Ala (mutant BpsOmp38Y119A) enhanced uptake of the antimicrobial agents, while substitution with Phe (mutant BpsOmp38Y119F) inhibited uptake.

References

• Ref 1: Functional reconstitution, gene isolation and topology modelling of porins from Burkholderia pseudomallei and Burkholderia thailandensis. Biochem J. 2004 Feb 1;377(Pt 3):579-87. doi: 10.1042/BJ20031118.
• Ref 2: Porin involvement in cephalosporin and carbapenem resistance of Burkholderia pseudomallei. PLoS One. 2014 May 1;9(5):e95918. doi: 10.1371/journal.pone.0095918. eCollection 2014.